ReviewTherapeutic advances in endocrinology and metabolism2020
Thyroid hormones and modulation of diastolic function: a promising target for heart failure with preserved ejection fraction.
Review in Therapeutic advances in endocrinology and metabolism, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 24 citations in OpenAlex.
- Virtual screening of compounds for the development of thyroid hormone analogues for potential application in cardiac regeneration.Journal of computer-aided molecular design · 2026Article
- Thyroid dysfunction and risk of atrial fibrillation in patients with hypertrophic obstructive cardiomyopathy: a multicenter cohort study.Frontiers in endocrinology · 2026Article
- Impact of Thyroid Hormone Imbalance on Electrocardiographic Parameters: Systematic Review and Meta-Analysis.Journal of clinical medicine · 2025Review
- Noncoding and coding mechanisms of aging-related heart failure with preserved ejection fraction associated with thyroid dysfunction.Disease models & mechanisms · 2025Article
- Impact of Metabolically Healthy Obesity on Cardiovascular Outcomes in Older Adults with HFpEF: Insights from a Nationwide Sample.Journal of clinical medicine · 2025Article
- Thyroid dysfunction in heart failure with preserved ejection fraction: A systematic review and meta-analysis.ARYA atherosclerosis · 2025Review
- An Overview of Cardiovascular Risk in Pituitary Disorders.Medicina (Kaunas, Lithuania) · 2024Review
- The association between TSH and thyroid hormones in the normal or subclinical dysfunction range with left ventricular diastolic dysfunction.Scientific reports · 2024Article
- Elucidating the role of phytocompounds fromIn silico pharmacology · 2024Article
- Renal function changes in patients with subclinical hyperthyroidism: a novel postulated mechanism.Endocrine · 2023Article
- Thyroid Hormone and Heart Failure: Charting Known Pathways for Cardiac Repair/Regeneration.Biomedicines · 2023Review
- Correlation between systemic inflammatory response index and thyroid function: 2009-2012 NHANES results.Frontiers in endocrinology · 2023Article
- Correlation Between Severity of Illness and Levels of Free Triiodothyronine, Interleukin-6, and Interleukin-10 in Patients with Acute Pancreatitis.Medical science monitor : international medical journal of experimental and clinical research · 2022Article
- Value of FT3/FT4 Ratio in Prognosis of Patients With Heart Failure: A Propensity-Matched Study.Frontiers in cardiovascular medicine · 2022Article
- Genome-wide methylation patterns in Marfan syndrome.Clinical epigenetics · 2021Article
- Is coronary artery tortuosity a precursor of atherosclerosis and/or left ventricular diastolic dysfunction?The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2021Article
- Thyroid Hormone Plays an Important Role in Cardiac Function: From Bench to Bedside.Frontiers in physiology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure with preserved ejection fraction (HFpEF) is a clinical syndrome with high mortality for which there is no proven therapy to improve its prognosis. Thyroid dysfunction is common in heart failure (HF) and is associated with worse prognosis. In this review, we discuss the cardiovascular effects of thyroid hormones, the pathophysiology of HFpEF, the prognostic impact of thyroid function, and the potential of thyroid hormones for treatment of HFpEF. Thyroid hormones have a central role in cardiovascular homeostasis, improving cardiac function through genomic and non-genomic mechanisms. Both overt and subclinical hypothyroidism are associated with increased risk of HF. Even when plasmatic thyroid hormones levels are normal, patients with HF may have local cardiac hypothyroidism due to upregulation of type 3 iodothyronine deiodinase. Thyroid hormones improve several pathophysiological mechanisms of HFpEF, including diastolic dysfunction and extra-cardiac abnormalities. Supplementation with thyroid hormones (levothyroxine and/or liothyronine), modulation of deiodinase activity, and heart-specific thyroid receptor agonists are potential therapeutic approaches for the treatment of HFpEF. Further preclinical and clinical studies are needed to clarify the role of thyroid hormones in the treatment of HFpEF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.